{"id":"chlorpropamide","rwe":[],"tags":[{"label":"Sulfonylurea","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sulfonylurea receptor 1, Kir6.2","category":"target"},{"label":"ABCC8","category":"gene"},{"label":"KCNJ11","category":"gene"},{"label":"A10BB02","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Diabetes mellitus type 2","category":"indication"},{"label":"Pfizer","category":"company"},{"label":"Approved 1950s","category":"decade"},{"label":"Hypoglycemic Agents","category":"pharmacology"}],"phase":"marketed","safety":{"drugInteractions":[{"url":"/drug/ciprofloxacin","drug":"ciprofloxacin","action":"Monitor closely","effect":"May interact with Ciprofloxacin","source":"DrugCentral","drugSlug":"ciprofloxacin"},{"url":"/drug/gatifloxacin","drug":"gatifloxacin","action":"Monitor closely","effect":"May interact with Gatifloxacin","source":"DrugCentral","drugSlug":"gatifloxacin"},{"url":"/drug/labetalol","drug":"labetalol","action":"Monitor closely","effect":"May interact with Labetalol","source":"DrugCentral","drugSlug":"labetalol"},{"url":"/drug/levofloxacin","drug":"levofloxacin","action":"Monitor closely","effect":"May interact with Levofloxacin","source":"DrugCentral","drugSlug":"levofloxacin"},{"url":"/drug/metoprolol","drug":"metoprolol","action":"Monitor closely","effect":"May interact with Metoprolol","source":"DrugCentral","drugSlug":"metoprolol"},{"url":"/drug/nadolol","drug":"nadolol","action":"Monitor closely","effect":"May interact with Nadolol","source":"DrugCentral","drugSlug":"nadolol"},{"url":"/drug/norfloxacin","drug":"norfloxacin","action":"Monitor closely","effect":"May interact with Norfloxacin","source":"DrugCentral","drugSlug":"norfloxacin"},{"url":"/drug/ofloxacin","drug":"ofloxacin","action":"Monitor closely","effect":"May interact with Ofloxacin","source":"DrugCentral","drugSlug":"ofloxacin"},{"url":"/drug/penbutolol","drug":"penbutolol","action":"Monitor closely","effect":"May interact with Penbutolol","source":"DrugCentral","drugSlug":"penbutolol"},{"url":"/drug/pindolol","drug":"pindolol","action":"Monitor closely","effect":"May interact with Pindolol","source":"DrugCentral","drugSlug":"pindolol"},{"url":"/drug/propranolol","drug":"propranolol","action":"Monitor closely","effect":"May interact with Propranolol","source":"DrugCentral","drugSlug":"propranolol"},{"url":"/drug/rifampicin","drug":"rifampicin","action":"Monitor closely","effect":"May interact with Rifampin","source":"DrugCentral","drugSlug":"rifampicin"},{"url":"/drug/sotalol","drug":"sotalol","action":"Monitor closely","effect":"May interact with Sotalol","source":"DrugCentral","drugSlug":"sotalol"},{"url":"/drug/timolol","drug":"timolol","action":"Monitor closely","effect":"May interact with Timolol","source":"DrugCentral","drugSlug":"timolol"},{"url":"/drug/voriconazole","drug":"voriconazole","action":"Monitor closely","effect":"May interact with Voriconazole","source":"DrugCentral","drugSlug":"voriconazole"}],"contraindications":["Asthenia","Breastfeeding (mother)","Disease of liver","Fever greater than 100.4 Fahrenheit","Glucose-6-phosphate dehydrogenase deficiency anemia","Heart disease","Hemolytic anemia","Hepatic porphyria","Hypoglycemic disorder","Hypopituitarism","Primary adrenocortical insufficiency","Prolonged-Severe Nausea and Vomiting","Surgical procedure","Traumatic injury"]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CHLORPROPAMIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:42:29.053282+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:42:34.493640+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CHLORPROPAMIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:42:34.951416+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Sulfonylurea receptor 1, Kir6.2 blocker","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:42:36.082264+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL498/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:42:35.738740+00:00"}},"allNames":"diabinese","offLabel":[],"synonyms":["chlorpropamide","chlorodiabina","chloronase","chloropropamide","chlorpropamid"],"timeline":[{"date":"1958-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from PFIZER to Pfizer"},{"date":"1958-10-28","type":"positive","source":"DrugCentral","milestone":"FDA approval (Pfizer)"}],"aiSummary":"Diabinese (Chlorpropamide) is a small molecule sulfonylurea that targets the sulfonylurea receptor 1 (SUR1) and Kir6.2 subunit of the ATP-sensitive potassium channel in pancreatic beta cells. It was originally developed by Pfizer and remains under their ownership. Diabinese is used to treat type 2 diabetes mellitus by stimulating insulin release from the pancreas. The drug is off-patent and has multiple generic manufacturers. Key safety considerations include hypoglycemia risk and potential interactions with other medications.","approvals":[{"date":"1958-10-28","orphan":false,"company":"PFIZER","regulator":"FDA"}],"brandName":"Diabinese","ecosystem":[{"indication":"Diabetes mellitus type 2","otherDrugs":[{"name":"acarbose","slug":"acarbose","company":"Bayer Hlthcare"},{"name":"acetohexamide","slug":"acetohexamide","company":"Lilly"},{"name":"albiglutide","slug":"albiglutide","company":"Glaxosmithkline Llc"},{"name":"alogliptin","slug":"alogliptin","company":"Takeda Pharms Usa"}],"globalPrevalence":537000000}],"mechanism":{"target":"Sulfonylurea receptor 1, Kir6.2","novelty":"First-in-class","targets":[{"gene":"ABCC8","source":"DrugCentral","target":"Sulfonylurea receptor 1, Kir6.2","protein":"ATP-binding cassette sub-family C member 8"},{"gene":"KCNJ11","source":"DrugCentral","target":"Sulfonylurea receptor 1, Kir6.2","protein":"ATP-sensitive inward rectifier potassium channel 11"}],"modality":"Small Molecule","drugClass":"Sulfonylurea","explanation":"","oneSentence":"","technicalDetail":"Diabinese binds to the sulfonylurea receptor 1 (SUR1) and Kir6.2 subunit of the ATP-sensitive potassium channel, inhibiting potassium efflux and depolarizing the beta cell membrane, which leads to an increase in insulin release through the closure of ATP-sensitive potassium channels."},"commercial":{"launchDate":"1958","_launchSource":"DrugCentral (FDA 1958-10-28, PFIZER)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/622","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CHLORPROPAMIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CHLORPROPAMIDE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T09:35:45.555961","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:42:37.376317+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"glibenclamide","drugSlug":"glibenclamide","fdaApproval":"1984-05-01","relationship":"same-class"},{"drugName":"tolbutamide","drugSlug":"tolbutamide","fdaApproval":"1961-06-22","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tolazamide","drugSlug":"tolazamide","fdaApproval":"1966-07-18","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"glipizide","drugSlug":"glipizide","fdaApproval":"1984-05-08","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"glimepiride","drugSlug":"glimepiride","fdaApproval":"1995-11-30","genericCount":17,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"acetohexamide","drugSlug":"acetohexamide","fdaApproval":"1964-12-23","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"chlorpropamide","indications":{"approved":[{"name":"Diabetes mellitus type 2","source":"DrugCentral","snomedId":44054006,"regulator":"FDA","usPrevalence":37300000,"globalPrevalence":537000000,"prevalenceMethod":"curated","prevalenceSource":"IDF Diabetes Atlas, 2024"}],"offLabel":[{"name":"Diabetes insipidus","source":"DrugCentral","drugName":"CHLORPROPAMIDE","evidenceCount":290,"evidenceLevel":"strong"}],"pipeline":[]},"currentOwner":"Pfizer","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"glibenclamide","brandName":"glibenclamide","genericName":"glibenclamide","approvalYear":"1984","relationship":"same-class"},{"drugId":"tolbutamide","brandName":"tolbutamide","genericName":"tolbutamide","approvalYear":"1961","relationship":"same-class"},{"drugId":"tolazamide","brandName":"tolazamide","genericName":"tolazamide","approvalYear":"1966","relationship":"same-class"},{"drugId":"glipizide","brandName":"glipizide","genericName":"glipizide","approvalYear":"1984","relationship":"same-class"},{"drugId":"glimepiride","brandName":"glimepiride","genericName":"glimepiride","approvalYear":"1995","relationship":"same-class"},{"drugId":"acetohexamide","brandName":"acetohexamide","genericName":"acetohexamide","approvalYear":"1964","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":["Diabetes Mellitus, Type 2","Cardiovascular Diseases"],"enrollment":714582,"completionDate":"2018-06-25"},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":["Diabetes Mellitus, Type 2"],"enrollment":1417914,"completionDate":"2015-04"},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":["Type 2 Diabetes Mellitus"],"enrollment":1499650,"completionDate":"2015-05"},{"nctId":"NCT02475499","phase":"","title":"Incretin-based Drugs and Pancreatic Cancer","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":["Diabetes Mellitus, Type 2"],"enrollment":886172,"completionDate":"2015-04"},{"nctId":"NCT01068860","phase":"PHASE2","title":"To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-02","conditions":["Type 2 Diabetes Mellitus","Impaired Glucose Tolerance"],"enrollment":246,"completionDate":"2010-08"},{"nctId":"NCT00004363","phase":"","title":"Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus","status":"COMPLETED","sponsor":"National Center for Research Resources (NCRR)","startDate":"1995-12","conditions":["Diabetes Insipidus","Diabetes Insipidus, Neurohypophyseal"],"enrollment":0,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000146198","MMSL":"4361","NDDF":"000910","UNII":"WTM2C3IL2X","VUID":"4017841","CHEBI":"CHEBI:3650","VANDF":"4017841","INN_ID":"790","RXNORM":"2404","UMLSCUI":"C0008287","chemblId":"CHEMBL498","ChEMBL_ID":"CHEMBL498","KEGG_DRUG":"D00271","DRUGBANK_ID":"DB00672","PUBCHEM_CID":"2727","SNOMEDCT_US":"111154004","IUPHAR_LIGAND_ID":"6801","MESH_DESCRIPTOR_UI":"D002747"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1958-","companyName":"Pfizer","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"46.0 hours","clearance":"0.045 mL/min/kg","bioavailability":"95%","fractionUnbound":"0.03%","volumeOfDistribution":"0.19 L/kg"},"publicationCount":1499,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"A10BB02","allCodes":["A10BB02"]},"biosimilarFilings":[],"originalDeveloper":"Pfizer","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":11,"_genericFilersChecked":true,"genericManufacturerList":["Ani Pharms","Dava Pharms Inc","Halsey","Par Pharm","Pharmobedient","Rising","Sandoz","Superpharm","Usl Pharma","Watson Labs","Watson Labs Teva"],"status":"approved","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"1958","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1958-10-28T00:00:00.000Z","mah":"PFIZER","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1958-10-28T00:00:00.000Z","mah":"PFIZER","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1958-10-28T00:00:00.000Z","mah":"PFIZER","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1958-10-28T00:00:00.000Z","mah":"PFIZER","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1958-10-28T00:00:00.000Z","mah":"PFIZER","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1958-10-28T00:00:00.000Z","mah":"PFIZER","brand_name_local":null,"application_number":""},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:42:37.376317+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}